Intravascular brachytherapy with gamma sources has been proved to prevent i
n-stent restenosis in recent clinical trials. Beta sources are also being i
nvestigated. The intravascular use of radioactive sources has raised theore
tical and logistic problems and renewed the interest in teletherapy for the
treatment and prevention of restenosis. We review the literature published
on the use of teletherapy in animal models and compare it to brachytherapy
from biological and logistic points of view. Developing technologies for s
tereotactic radiotreatment of moving targets may offer new solutions and ar
e being studied.